<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advocacy &amp; Public Policy</td>
<td>6</td>
</tr>
<tr>
<td>Research</td>
<td>8</td>
</tr>
<tr>
<td>MDA Care Center Network</td>
<td>10</td>
</tr>
<tr>
<td>MDA Clinical &amp; Scientific Conference</td>
<td>12</td>
</tr>
<tr>
<td>Quest Media</td>
<td>14</td>
</tr>
<tr>
<td>Programs &amp; Support</td>
<td>16</td>
</tr>
<tr>
<td>Volunteers</td>
<td>20</td>
</tr>
<tr>
<td>Recreation Programs</td>
<td>22</td>
</tr>
<tr>
<td>Community Programs</td>
<td>26</td>
</tr>
<tr>
<td>Fundraising Events</td>
<td>28</td>
</tr>
<tr>
<td>Partners</td>
<td>30</td>
</tr>
<tr>
<td>Committees</td>
<td>32</td>
</tr>
<tr>
<td>Financial Report</td>
<td>39</td>
</tr>
</tbody>
</table>
Dear MDA Families, Partners, and Friends,

It’s my privilege to share with you a comprehensive report on MDA’s mission impact in 2023. Your participation in our work created opportunities for enduring impact across our community of children, adults and families living with neuromuscular disease. As you’ll read further in our report, we achieved remarkable milestones in 2023.

We saw unprecedented output from our drug development pipeline of progress with FDA approval of eight new drugs and formulations. Notably, two new genetic therapies were approved, and we expect to see more coming forward in 2024.

With your support, we funded over 145 research grants totaling $35 million, driving further progress in the way we understand and treat neuromuscular diseases.

MDA led important global conversations with leading researchers, clinicians and regulatory agencies on translational research and elevating the patient experience in the way we design research, treatment and care processes.

Our advocacy work on Capitol Hill and in White House policy discussions, positively influenced long-awaited changes that will redefine the way travelers with neuromuscular and other disabilities can fly without fear of injury or damage to mobility devices like power wheelchairs.

Also this year, you put broad and lasting smiles on the faces of 800 children and young adults participating in MDA’s beloved Summer Camp tradition. Your partnership also enabled us to launch incredible initiatives that are being unveiled in 2024, including new ways to experience MDA’s vast educational and informational resources, and our new College Scholarship program.

Your 2023 commitment to children, adults, and families living with neuromuscular disease has laid the foundation for continuous impact and momentum. As we continue to move forward in this new age of treatments, inclusion and unity, we are proud and grateful that you choose to stand with us. We could not do this work without you.

With deepest gratitude,

Donald S. Wood, Ph.D.
President & CEO
Muscular Dystrophy Association
In 2023, MDA’s Public Policy and Advocacy efforts achieved significant milestones, marking a transformative year for legislative progress and community empowerment. We showcased MDA’s unwavering dedication to advocating for policies that empower and enhance the lives of people with neuromuscular diseases. Through strategic engagement, collaborative partnerships, and relentless advocacy, MDA continues to champion transformative change for the community it serves.

MDA on the Hill

After a hiatus due to the pandemic, MDA’s advocates returned to Capitol Hill in May 2023, advocating for accessible air travel. Thirty-one advocates from eleven states participated, engaging in 31 meetings with key lawmakers. Their strategic approach targeted decision-makers crucial to advancing air travel legislation, yielding impactful results.

MDA’s relentless advocacy led to the passage of the House’s version of the Federal Aviation Act (FAA) reauthorization. This bill heralds the most substantial air travel accessibility reforms since the 1980s, setting the stage for continued progress in 2024. Additionally, thanks to years of MDA advocacy efforts, the Department of Transportation (DOT) released regulations mandating accessible lavatories on single aisle airplanes with shorter implementation timelines.

In November, MDA announced a groundbreaking partnership with the Transportation Security Administration (TSA) to train officers on interacting with travelers with neuromuscular diseases, prioritizing safety, comfort, and dignity. This collaboration, including educational materials developed by MDA, promises to enhance the travel experience for individuals relying on mobility devices.
MDA’s relentless advocacy led to the passage of the House’s version of the Federal Aviation Act (FAA) reauthorization.

Access to Care and Equipment

MDA’s advocacy extended to healthcare access, with pivotal achievements such as advancing Duchenne muscular dystrophy (DMD) screening for newborns and securing Medicare coverage for wheelchair seat elevation systems. These victories exemplify MDA’s commitment to ensuring equitable access to vital care and equipment for individuals with neuromuscular diseases.

Advocacy Collaboration Grants

MDA awarded over $100,000 in Advocacy Collaboration Grants to five organizations. These grants support innovative projects aimed at driving positive policy outcomes at federal, state, and local levels, fostering collaboration and amplifying advocacy efforts.
Leadership in the Era of Genetic Medicine

As genetic therapies enter clinical testing, MDA remains at the forefront, driving discussions on safety and clinical translation. In 2023, MDA participated in critical meetings at the National Institutes of Health (NIH) and hosted its second gene therapy summit, convening key stakeholders to address challenges in clinical translation. Notably, MDA’s collaboration with CureDuchenne and Parent Project Muscular Dystrophy led to the funding of a clinical study, spearheaded by MDA’s Chief Medical Advisor, Dr. Barry Byrne, to explore novel strategies for enhancing gene therapy inclusivity. In the words of Dr. Barry Byrne, “Our goal now is to figure out how to best maximize and achieve the biggest impact with the technology in our hands.” With unwavering dedication and collaborative efforts, MDA continues to drive progress and innovation, ushering in a new era of hope and possibilities for individuals and families affected by neuromuscular diseases.

Nurturing Future Leaders in Research

MDA’s commitment to cultivating the next generation of researchers is evident through initiatives like the Development Grant program, which has supported over 2500 early-stage scientists and clinicians with $126 million in funding. In 2023, MDA awarded eight new trainees through its fellowship program and launched the Summer Undergraduate Research Experience (SURE) program, providing invaluable research opportunities for students from underrepresented backgrounds. These efforts will cultivate a diverse and skilled workforce dedicated to advancing neuromuscular disease research.
A New Era of Treatments

2023 heralded a groundbreaking milestone with the FDA’s approval of eight drugs and formulations for various neuromuscular diseases, marking the most significant year in drug approvals to date. Notably, the approval of the first genetic medicines for ALS and Duchenne muscular dystrophy represents a culmination of decades of MDA-funded research into disease-causing genes. These approvals underscore MDA’s pivotal role in advancing genetic medicine and signal a transformative shift in disease management, offering hope for patients worldwide.

Mentor Matthew Alexander

"I enjoyed training an undergraduate student and seeing them get excited about a neuromuscular project. It is always very rewarding to get them interested at an early stage and see them visualize a career in the neuromuscular field."
The MDA Care Center Network experienced substantial growth, awarding $6M+ in Care Center grants. With 150+ Care Center Network sites, including MDA Care Centers, MDA ALS Centers, and Care Affiliates, the network provided vital care and support to over 70,000 unique patients at over 120,000 visits.

Strategic initiatives, including recertification efforts and enrollment, ensured the continued high standards for excellence and accessibility of Care Centers. Additionally, the launch of the Associated Provider Network program expanded community support and outreach, reaching expanded MDA awareness to other providers in effort to increase path to diagnosis for experts to know when to refer.
In 2023, MDA hosted its prestigious annual Clinical and Scientific Conference, a cornerstone event that brings together leading researchers, clinicians, and healthcare professionals dedicated to advancing the field of neuromuscular diseases. The conference featured groundbreaking presentations, collaborative workshops, and extensive networking opportunities, fostering an environment of innovation and shared knowledge.

A highlight of the conference was the presentation of the MDA Scientific Achievement Award to Dr. Peter Marks from the FDA. Dr. Marks was honored for his significant contributions to the field of neuromuscular disease research and regulation. His work has been instrumental in advancing new therapies and ensuring their safe and effective delivery to patients.

The MDA Clinical and Scientific Conference continues to be an essential platform for driving progress and inspiring collaboration within the neuromuscular disease community, reinforcing MDA’s commitment to research excellence and improved patient outcomes.

Dr. Marks was honored for his significant contributions to the field of neuromuscular disease research and regulation.
1,942 in-person attendees from 18 countries
567 virtual live-stream attendees from 33 countries

265 posters
55 exhibitors
236 virtual posters
The Quest Media Platform serves the neuromuscular disease and other disability communities as a vital hub of well-researched information about adaptive lifestyles, current research and treatment options, adaptive products for work, play and home, challenges and opportunities facing families with disabilities affecting mobility, and policy news from Capitol Hill, National Institutes of Health and other legislative and regulatory agencies. Through its comprehensive suite of digital tools and resources, the platform empowers individuals to access valuable educational content, connect with peers and experts, and support to help people advocate for themselves, their children, partners and other loved ones.

Expanding Reach and Impact

With its focus on inclusivity and accessibility, the platform attracted users from diverse backgrounds and communities, fostering a sense of belonging and support for all individuals affected by neuromuscular diseases. Throughout 2023, the Quest Media Platform witnessed unprecedented growth and engagement, reaching an ever-expanding audience of patients, caregivers, researchers, and advocates. Quest’s digital traffic increased from approximately 5,000 visits per month in 2022 to approximately 20,000 visits per month in 2023 – and there is no slowing down in sight.

Building upon the success of the 2022 gift and giving guide, we partnered even more closely with the MDA ambassador team and launched the evergreen Quest Media product guide. The product guide is updated quarterly with new ambassadors recommending new products.

Facilitating Knowledge Sharing and Collaboration

One of the highlights of the Quest Media Platform’s success in 2023 was its role in facilitating knowledge sharing and collaboration within the neuromuscular disease community. Through interactive forums, webinars, and virtual events, users had the opportunity to exchange insights, share experiences, and collaborate on initiatives aimed at advancing research and improving patient care.

Elevating Patient Voices

Central to the success of the Quest Media Platform is its commitment to amplifying the voices and experiences of patients and caregivers. Through user-generated content, personal stories, and testimonials, the platform provided a space for people to share their journeys, inspire others, and advocate for greater awareness and support for neuromuscular diseases.
Quest’s Digital Traffic 2022-2023

- Approximately 5,000 visits per month in 2022
- Approximately 20,000 visits per month in 2023
In 2023, MDA accommodated significant growth and generated corresponding impact across its various programs and initiatives, reaffirming its commitment to serving children, adults, and families living with neuromuscular diseases.

Resource Center
The MDA Resource Center emerged as a pillar of support for the MDA community, handling 10K+ requests in 2023. With an average response time of less than a day, the Resource Center swiftly addresses inquiries, providing essential information and guidance on care, resources, and financial assistance. Inbound call statistics showcased the center’s responsiveness, with an 83% connection rate for inbound calls and a 91% connection rate for outbound calls.

MDA’s Resource Center swiftly addresses inquiries, providing essential information and guidance on care, resources, and financial assistance.

17K+ cases in 2023
Medical Education

In 2023, MDA’s Medical Education program made significant strides in professional education. The Allied Health Symposia, focus groups and workshops provided valuable learning opportunities. The program also featured four continuing education accredited Grand Rounds webinars, drawing substantial interest with 800+ registrations. Engagement was high, with 325+ live attendees and an impressive 2,300+ on-demand views, highlighting the program’s broad reach and impact to the medical community.

Gene Therapy Support Network

In 2023, the Muscular Dystrophy Association launched the MDA Gene Therapy Support Network, including a dedicated “MDA Gene Team”. This expansion underscores our commitment to the NMD community and the MDA Care Center Network to facilitating access to advanced gene therapy treatments for people living with neuromuscular diseases.

$125M+

invested in advancing gene therapy (GTx) for neuromuscular diseases
MDA Community Education programs support people and families impacted by neuromuscular disease through the delivery of relevant, responsive, and actionable content from key opinion leaders. These programs focus on navigating critical life transitions, increasing disease understanding, and supporting access to independence.

**MDA Access Workshops**

On-demand learning focused on increasing health literacy, empowerment, and self-advocacy to overcome barriers to education, employment, insurance, equipment and more.

“Thank you for putting together such an interesting and informative day. It gives me motivation to look into additional ways to help myself and make living with this disorder more tolerable.”

— MDA Engage Attendee
MDA Engage Seminars

MDA Engage Seminars provide live and on-demand virtual programs focus on providing in depth information about a specific disease or topic relevant to the neuromuscular disease community. 2023 saw the long-awaited return to in-person programming, at three MDA Engage symposiums that engaged 57 clinicians, representatives from 11 care centers, nearly 200 participants and over $312,000 in funding secured.

Print-ready Educational Materials

Including disease fact sheets, at-home physical therapy guides, emergency room alert cards, and more. Many of these materials are also available in Spanish.

ONEvoice Community Insights

Structured opportunities for MDA to hear and learn from the neuromuscular disease community through surveys and family roundtables.

MDA Mentorship Program

MDA’s mentorship program is designed to increase the number of people living with neuromuscular disease in the workforce by connecting youth to mentors who are established in a variety of fields, while providing hands-on learning in a supportive environment to discover their strengths and interests. In 2023, the program expanded to include a separate 5-week session for younger teens to explore a variety of careers.

A STEM focused session, now in its third year, serves young adults ages 16-21 who are specifically interested in STEM careers (science, technology, engineering, and math). Participants work with mentors from a specific field to complete an interactive project while also diving deeper into the ins and outs of STEM related fields.

40 young people and 28 mentors participated in the MDA Mentorship Program in 2023.
In a resounding declaration of respect and gratitude, MDA President & CEO Don Wood designated 2023 as The Year of the Volunteer, honoring the backbone of MDA—its dedicated volunteers. For over seven decades, MDA has been powered by selfless people from all walks of life who have helped shape MDA’s legacy and its impact on adults, children, and families living with neuromuscular disease.

MDA’s Year of the Volunteer led to revitalized communication and engagement with volunteers around the country. This initiative included work to refine data systems, ensuring more meaningful and effective interactions. It also provided a platform to celebrate volunteers with spotlight stories about their experiences and motivations for choosing to dedicate their time and their hearts to MDA and its community.

In 2023 alone, MDA attracted 850 volunteers from over 1600 applicants. Together, the 2023 cohort of volunteers contributed over 60,000 hours (about 7 years) to support mission programs. This includes volunteers who supported 800+ children with neuromuscular diseases at MDA’s Summer Camp and advised fifty young mentorship and STEM participants. MDA volunteers also generated over 3,500 letters to elected officials advocating for consideration of policy reforms that would remove barriers to inclusion, safety and security for people with neuromuscular conditions. Ninety of our volunteers represent the MDA Ambassador program, who share their stories with the greater community to emphasize the need for MDA’s continued innovations in neuromuscular medicine and research, advocacy and community-building.

60,000+ hours (the equivalent of 7 years!) to mission programs
“It was honestly the best week of my life. The happiness brought to the kids was so contagious that I’ve never felt this happy before. I will definitely be coming back next year and would recommend everyone to be a part of this beautiful experience.”

- Volunteer from Florida Elks Camp, FL

“Camp is pure magic. If you’ve been once, it’s the easiest decision in the world to return year after year.”

- Volunteer from Timber Pointe Outdoor Center, IL

“I started volunteering at MDA Camp in 2018 as a medical provider. I know many of the campers from Care Center and camp provides a space I am able to bond with them in a different setting. I am able to witness the campers have opportunities they would not experience outside of the camp. Camp provides them adaptabilities to have a true summer camp experience! MDA Camp has become the best week of the year for me also and I look forward to it every summer!”

- Kathryn S. CPNP, Medical Team Volunteer & MDA Care Center Team Member
Through our recreation programs, we provide MDA community members and their families with unique opportunities for inclusive leisure-time activity and connection that yield independence, empowerment, and lasting relationships.

**Summer Camp**

In 2023, MDA welcomed 800+ campers and 570 volunteers to 22 in-person and two virtual camp experiences.

MDA Summer Camp is a beloved tradition for generations of children and the volunteers who support their camp experience. Camp is where barriers fade away and where kids with neuromuscular diseases can thrive in a fully adaptive environment designed to help them try new experiences and to build lifelong friendships as they acquire essential life skills, such as self-advocacy.

“This summer was my second time going to MDA Summer Camp. Whenever I go to camp, I feel so welcomed and loved. MDA Camp is a place where you create lifelong friendships – this summer I got to see some of my old friends and make new ones. It is always so nice to have people who understand me, and I can relate to. MDA Camp is truly a place of acceptance and rejuvenation. I would like to thank all of the nurses and volunteers for making MDA Camp possible. Thank you for giving me and so many others so much joy.”

- Leah, MDA NJ Camper and MDA National Ambassador

“MDA camp has been the highlight of my summers since I was eight. It has taught me how to come out of my shell and make new friends. Those friendships have now become permanent and ones that I look forward to reestablishing every summer. Camp is where I feel most comfortable and where I want to be.”

- Abby, MN Camper
97% of parents value the summer camp program and the effect it has had.

96% of parents shared that summer camp has helped their child become more independent.

96% of parents say that camp has helped their child increase their confidence levels.
“I am absolutely amazed at my son’s confidence and self-reliance after just one week at camp! Thank you, MDA, volunteers, and sponsors!”

- Camper Parent

“My son LOVES camp!! It is the only place in the world, besides our home, that I think he doesn’t feel like an outsider, a burden, a spectacle, or just too different. It brings him so much joy to go every year, & he is always sad to leave & have to wait another year for the experience.”

- Camper Parent
MDA's Family Getaway Program was introduced in 2023 to offer meaningful experiences for families living with neuromuscular disease. Family Getaway weekends provide opportunities for families to bond and connect with the broader MDA community while enjoying a variety of accessible activities in fully accessible resort locations. With four sites hosting forty-six families and 150+ attendees and 17 volunteers, the impact of these getaways extends far beyond the weekend itself.

Puerto Rico Family Getaway Participant

“I loved this, I needed this, I feel like I finally found my planet. Everybody here is like me, I don’t even have this at my ‘home’ because here we all have the same pain, they walk, run and jump around like I do.”

46 Families
4 Sites
153 Attendees
Community Programs

Cultivating Connection & Belonging

Community Programs at MDA empower members of the neuromuscular disease community to make social connections, bond over shared hope, raise awareness, and feel a sense of belonging.

Let’s Play
MDA Let’s Play brings the fun and joy of a community center to individuals’ homes. Using the online platform Discord, MDA provides community members with a safe and welcoming environment online. We provide all 2,500+ community members with entertainment through gaming, art, content creation, and other activities while socializing with others who can truly understand the unique situations in everyone’s lives. It is our goal to enable members to both be themselves and share themselves while instilling a sense of belonging for all.

MDA Ambassadors
MDA Ambassadors are young people and adults living with neuromuscular disease who share their stories and authentic perspectives to connect within the community to raise awareness, inspire support, and advance the MDA mission. Ambassadors share their story and experiences in print, on video, at MDA events, and more, engaging with MDA’s partners and the greater community to spread awareness and garner support. In 2023, MDA was represented by 102 Ambassadors, including two National Ambassadors, one child and one adult. MDA Ambassadors share their stories to raise awareness and hope, while reflecting the breadth and diversity of the neuromuscular community.
Amy Shinneman
2023 MDA National Ambassador

“When I set out on this journey as National Ambassador, making connections with others through sharing my story was one of my main objectives. I have met many great people living with neuromuscular disease, as well as some of their families. These connections have been life changing for me and motivate me to continue to share my story even after my role as an MDA National Ambassador is over. Meeting fellow National Ambassador Leah and her family has been a highlight as well. Our families will be friends for a long time to come!”

Leah Zelaya
2023 MDA National Ambassador

“I am so grateful for the opportunities that I have had in my life to represent people with disabilities. I am blessed that I have been able to do this through the arts and ambassadorship. Being this year’s National Ambassador for MDA has been a dream come true. It has been so rewarding to be able to share my story with others in order to raise awareness and encourage others living with neuromuscular disease. I am DEFINITELY living my BEST life! (Thank you, MDA!)”
Fundraising Events
Empowering Communities to Make a Difference

Team Momentum
4 marathons and 1 half marathon
$540k+ raised
168 participants

Muscle Walk
7 live events and 1 virtual
Over $869k raised
2,200+ participants
140 volunteers
239 Muscle Walk teams
“Sharing our son’s diagnosis was not an easy decision, but my good friends reminded me that now was the time to lean on my village, and that they were part of our family’s village. Hearing that instantly brought me comfort. From that moment, I knew that we were not alone in this journey, and it is a reminder that we all need a village to lean on during difficult times and that having a strong support system can make all the difference.”

– Team Milo, 2023 First Year Muscle Walk Participant
MDA’s corporate partners play a pivotal role in advancing our mission to transform the lives of people living with neuromuscular diseases. Through strategic alliances, these partners provided essential support, funding, and resources that fueled groundbreaking research, enhanced care, and raised awareness.

**IAFF | International Association of Fire Fighters**
- raised $700M since 1954

**CITGO**
- raised $272M in 38 years

**Acosta Group**
- raised $100M in 38 years

**Price Chopper**
- raised $30M in 39 years

**Dutch Bros**
- raised $2.5M in 2023
Partners

Visionary ($1M - $5M)
- acosta
- Safeway Foundation
- Dutch Bros

Leader ($500K - $1M)
- Biogen
- Burn Boot Camp
- Ride for Life

Innovator ($250K - $499K)
- Argenx
- Circle K
- Edgewise Therapeutics
- BD Morse Automotive Group
- Fareway

Transformer ($5M+)
- CIF
- Citgo

31
For close to 75 years, the Muscular Dystrophy Association has pioneered advancements in research, care, and advocacy for individuals and families living with neuromuscular diseases. As we approach this significant milestone, we reflect on our past achievements and look forward to a future filled with hope and continued progress.

MDA’s Board of Directors continues to steer the organization with a forward-thinking mission and a clear vision for the future. Our board is a diverse group of leaders, including top researchers, clinicians, entrepreneurs, business executives, disability advocates, and philanthropists. This distinguished panel of advisors brings exceptional wisdom, experience, and dedication. Their expertise and commitment ensure that MDA remains the leading voluntary health organization for the neuromuscular disease community in the US, empowering families and strengthening the communities in which they live.

In addition to their professional expertise, the members of our board bring a deep personal commitment and connection to MDA’s mission. This personal investment adds a layer of empathy and understanding that is reflected in all aspects of MDA’s work.

With the strong leadership and vision of our Board of Directors, we will continue to ensure that every person with neuromuscular disease can live longer, more independent lives.

“

Inspired by the volunteers who made such a difference in my life, I chose to give back and advocate for others facing similar challenges. This path of service led me through my academic and professional career, eventually to my role as a judge in New York State. It’s a journey that illustrates the transformative power of volunteering—not just for those we help, but for us as volunteers.

- Honorable Robert E. Pipia
  New York District Court
Governor Brad Henry  
Chairman  
26th Governor of Oklahoma  
Member of the Executive Committee of the Board

Christopher Rosa, PhD  
President & CEO of The Viscardi Center

Donald S. Wood, PhD  
President & CEO of the Muscular Dystrophy Association  
Member of the Executive Committee of the Board

Anjan Aralihalli  
Venture Partner, CTI Life Sciences

John R. Costantino, Esq.  
Managing General Partner, NGN Capital, LLC (Ret.)  
Member of the Executive Committee of the Board

Benjamin Cumbo, III  
Former Government Executive (Ret.)

Dan Fries  
Senior Vice President, Managing Director, Segal

Steve Furnary  
Founding Equity Partner of Clarion Partners

Jennifer Gottlieb  
Global President at Real Chemistry

John Howell  
President & Co-Founder, ComSovereign Holding

Nancy Kindelan  
Former Non-Profit CEO (Ret.)  
Member of the Executive Committee of the Board

Louis Kunkel, PhD  
Professor of Pediatrics and Genetics, Program in Genomics, Children’s Hospital Boston  
Member of the Executive Committee of the Board

Elizabeth McNally, MD, PhD  
Professor, Department of Biochemistry & Genetics, Northwestern University

Hon. Robert Pipia  
Judge, Nassau County District Court  
Member of the Executive Committee of the Board

Mike Rowlett  
Former CEO of Womack Machine Supply Company

Matt Plummer  
Designer, Matt Plummer Designs

Charles D. Schoor, Esq.  
Former Law Firm Partner (Ret.)  
Member of the Executive Committee of the Board

Tom Simon  
Assistive Technology Professional  
NuMotion

Mark Smith  
Chief Financial Officer and Corporate Secretary, Guidon Energy  
Member of the Executive Committee of the Board

Eugene Williams  
Chairman and CEO at ProMIS™ Neurosciences, Inc.

Lilian Wu, PhD  
Former Executive, IBM Global

IN MEMORIA

Victor Wright  
Former Partner of Goldman Sachs & Co (Ret.)

EMERITUS MEMBERS OF THE BOARD

Dr. Stanley Appel  
Co-Director of Houston Methodist Neurological Institute, Chair of the Stanley H. Appel Department of Neurology, Peggy and Gary Edwards Distinguished Chair in ALS at Houston Methodist Hospital, and Professor of Neurology at Weill Cornell Medical College

Bart Connor  
1984 Olympic Gold Medal Gymnast, SEC/ESPN/ABC Commentator and Inspirational Speaker

Olin Morris  
Former President and General Manager of New York Times Broadcast Group

Dr. R. Rodney Howell  
Professor and Chairman of Pediatrics Emeritus at Miller School of Medicine, University of Miami
Audit Committee Members

Mark Smith
Chairperson
Chief Financial Officer and Corporate Secretary, Guidon Energy

Lilian Wu
Former Executive, IBM Global

Christopher Rosa
President & CEO of The Viscardi Center

Gov. Brad Henry
26th Governor of Oklahoma

Compensation Committee Members

Honorable Robert Pipia
Chairperson
Nassau County District Court

Christopher Rosa
President & CEO of The Viscardi Center

Gov. Brad Henry
26th Governor of Oklahoma

Executive Committee Members

Mark Smith
Chairperson
Chief Financial Officer and Corporate Secretary, Guidon Energy

Honorable Robert Pipia
Nassau County District Court

Charles D. Schoor, Esq.
Former Law Firm Partner (Ret.)

John Costantino
Managing General Partner, NGN Capital, LLC (Ret.)

Finance and Investment Committee Members

John Costantino
Chairperson
Managing General Partner, NGN Capital, LLC (Ret.)

Dan Fries
Senior Vice President, Managing Director, Segal

Steve Furnary
Founding Equity Partner of Clarion Partners

John Howell
President & Co-Founder, ComSovereign Holding

Charles D. Schoor, Esq.
Former Law Firm Partner (Ret.)

Nancy Kindelan
Former Non-Profit CEO (Ret.)

Governance Committee

Charles D. Schoor, Esq.
Chairperson
Former Law Firm Partner (Ret.)

Beth McNally
Lorem ipsum dolor sit amet

Nancy Kindelan
Former Non-Profit CEO (Ret.)

Benjamin Cumbo III
Former Government Executive (Ret.)

Mike Rowlett
Former CEO of Womack Machine Supply Company

Matt Plummer
Designer, Matt Plummer Designs

Honorable Robert Pipia
Former Government Executive (Ret.)

AJ Aralihalli
Venture Partner, CTI Life Sciences

Development Committee Members

Nancy Kindelan
Former Non-Profit CEO (Ret.)

Anjan Aralihalli
Venture Partner, CTI Life Sciences

Mike Rowlett
Former CEO of Womack Machine Supply Company

Adam Gerber
Head of Ads Commercialization, Netflix

Research Advisory Committee 1 Members

Louis Kunkel, PhD
Chairperson
Boston Children’s Hospital, MA

Elisabeth Barton, PhD
University of Florida, FL

Aaron Beedle, PhD
SUNY Binghamton, NY

Andrew Berglund, PhD
University at Albany, NY

Sanjay Bidichandani, MBBS, PhD
University of Oklahoma, OK

Dean Burkin, PhD
University of Nevada, NV

James Dowling, M.D., PhD
Hospital for Sick Children, CAN
2023 COMMITTEE MEMBERS

Research Advisory Committee 1 Members Cont’d

Vandana Gupta, PhD
Brigham and Women’s Hospital, MA

Lawrence Hayward, M.D., PhD
University of Massachusetts, MA

Michio Hirano, M.D.
Columbia University, NY

Jyoti Jaiswal, PhD
Children’s National Research and Innovation Campus
Washington, DC

Peter Kang, M.D.
University of Minnesota Medical School, MN

Dwi Kemaladewi, PhD
University of Pittsburgh School of Medicine, PA

Linda Kusner, PhD
George Washington University, DC

Giovanni Manfredi, M.D., PhD
Weill Cornell Medical College, NY

Katherine Mathews, M.D.
University of Iowa, IA

Lynn Megeney, PhD
Ottawa Health Research Institute, CAN

Carlos Moraes, PhD
University of Miami, FL

Udai Pandey, PhD
University of Pittsburgh, PA

Rita Perlingeiro, PhD
University of Minnesota, MN

Rita Sattler, PhD
Barrow Neurological Institute, AZ

Christine Vande Velde, PhD
University of Montreal, CAN

Stephan Züchner, M.D., PhD, FAAN
University of Miami Miller School of Medicine, FL

Joel Chamberlain, PhD
University of Washington School of Medicine, WA

Yi-Wen Chen, DVM, PhD
Children’s National Research Institute, Washington, DC

Thomas Cooper, M.D.
Baylor College of Medicine, TX

Charles Emerson, PhD
University of Massachusetts Medical School, MA

Fen-Biao Gao, PhD
University of Massachusetts Medical School, MA

Matthew Harms, M.D.
Columbia University, NY

Nicholas Johnson, M.D.
Virginia Commonwealth University, VA

Joe Kornegay, D.V.M., PhD
Texas A & M University, TX

Clothilde Lagier-Tourenne, M.D., PhD
Massachusetts General Hospital, MA

Christian Lorson, PhD
University of Missouri, MO

Nicholas Maragakis, M.D.
Johns Hopkins University, MD

Joseph Metzger, PhD
University of Minnesota, MN

Kathrin Meyer, PhD
Nationwide Children’s Hospital, OH

Daniel Michele, PhD
University of Michigan Medical School, MI

Douglas Millay, Ph.D.
Cincinnati Children's Hospital Medical Center, OH

Brett Morrison, M.D., PhD
Johns Hopkins University, MD

Research Advisory Committee 2 Members

Elizabeth McNally, M.D., PhD
Chairperson
Northwestern University, IL

Matthew Alexander, PhD
Children’s of Alabama/University of Alabama at AL
Birmingham, AL

Alan Beggs, PhD
Boston Children's Hospital/Harvard Medical School, MA

Robert Bloch, PhD
School of Medicine, University of Maryland, Baltimore, MD
2023 COMMITTEE MEMBERS

2023 MDA Venture Philanthropy (MVP) Program Advisory Committee

Suma Babu, MBBS, MPH
Massachusetts General Hospital / Harvard Medical School

Alan Beggs, Ph.D.
Boston Children's Hospital / Harvard Medical School

Robert Bloch, Ph.D.
University of Maryland

Jeffrey Chamberlain, Ph.D.
University of Washington School of Medicine

Stephen Chang, Ph.D.
Independent NMD Consultant

Merit Cudkowicz, M.D., MSC
Massachusetts General Hospital / Harvard Medical School

Tania Gendron, Ph.D.
Mayo Clinic

Dione Kobayashi, Ph.D.
Mass General Brigham

Louis Kunkel, Ph.D.
Boston Children's Hospital / Harvard Medical School

Clothilde Lagier-Tourenne, M.D., Ph.D.
Massachusetts General Hospital / Harvard Medical School

Melanie Leitner, Ph.D.
Brown University / Accelerating NeuroVentures, LLC

Elizabeth McNally, M.D., Ph.D.
Northwestern University

John Porter, Ph.D.
Independent NMD Consultant

April Pyle, Ph.D.
David Geffen School of Medicine at UCLA

Robert Rugani
Independent Business Consultant

Rita Sattler, Ph.D.
Barrow Neurological Institute

Michael Shy, M.D.
University of Iowa

Noah Weisleder, Ph.D.
Ohio State University

Bruce Wentworth, Ph.D
Independent NMD Consultant

Stephan Züchner, M.D., Ph.D., FAAN
University of Miami Miller School of Medicine

2023 MDA Neuromuscular Observational Research (MOVR) Research Advisory Committee (RAC)

James Berry, MD, MPH
Harvard University Massachusetts General Hospital
Director, MGH Neurological Clinical Research Institute (NCRI) Chief, Division of ALS and Motor Neuron Diseases

Barry Byrne, MD, PhD
University of Florida
Associate Chair of Pediatrics

John Day, MD, PhD
Stanford University Medical Center
Professor of Neurology, of Pediatrics (Genetics) and, By Courtesy, of Pathology

R. Rodney Howell, MD
University of Miami
Professor and Chairman of Pediatrics Emeritus
Miller School of Medicine

Monkol Lek, PhD
Yale University
Assistant Professor

Nicholas Maragakis, MD
Johns Hopkins Medicine
Director, ALS Center for Cell Therapy and Regeneration Research Professor of Neurology

Sabrina Paganoni, MD, PhD
Harvard University Massachusetts General Hospital
Co-Director, MGH Neurological Clinical Research Institute (NCRI)
Assistant Professor

Eric Schultz
Ocean Genomics, Inc.
Co-Founder, Strategic Advisor
When my son Franklin was diagnosed with Duchenne muscular dystrophy (DMD), our family faced an unexpected journey. Thankfully, we found incredible support through MDA, which has been lifechanging. From connecting us with other families to providing the latest information on research and treatments, MDA has been with us every step of the way.

- Jay Griffin
MDA Executive Leadership

President and Chief Executive Officer
Donald S. Wood, Ph.D.

Chief Research Officer
Sharon Hesterlee, Ph.D.

Chief Operating Officer & Chief Financial Officer
Michael J. Kennedy, MBA, CPA

Chief Marketing Officer
Morgan Roth

Chief Legal Officer, General Counsel
Henry Lanman

Chief Development Officer
Ruth Ann Dailey

Executive Vice President, Healthcare Services
Nora Capocci, MPH

Executive Vice President, Community Engagement
Alicia Dobosz

Executive Vice President, Human Resources & Volunteers
Peri Gondim

Executive Vice President, Public Policy & Advocacy
Paul Melmeyer
# Financial Report

**($ in Thousands)**

<table>
<thead>
<tr>
<th></th>
<th>2023</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Revenue</td>
<td>$63,971</td>
<td>$51,067</td>
</tr>
</tbody>
</table>

## Functional Expenses

<table>
<thead>
<tr>
<th>Service</th>
<th>2023</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient and community services</td>
<td>20,277</td>
<td>19,839</td>
</tr>
<tr>
<td>Research</td>
<td>9,446</td>
<td>6,423</td>
</tr>
<tr>
<td>Professional public health education</td>
<td>13,150</td>
<td>12,224</td>
</tr>
<tr>
<td>Total program services</td>
<td>42,873</td>
<td>38,486</td>
</tr>
<tr>
<td>Fundraising</td>
<td>14,732</td>
<td>16,008</td>
</tr>
<tr>
<td>Management and general</td>
<td>3,833</td>
<td>3,502</td>
</tr>
<tr>
<td>Total expenses</td>
<td>61,438</td>
<td>57,996</td>
</tr>
</tbody>
</table>

## Other Non-Operating

<table>
<thead>
<tr>
<th>Description</th>
<th>2023</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Changes in unrecognized benefit plan costs</td>
<td>(948)</td>
<td>9,016</td>
</tr>
</tbody>
</table>

| Change in net assets                           | $1,585 | $2,087 |

## Revenue

- **Direct Contributions**: 18%
- **Other Revenue**: 12%
- **25% Growth in Revenue**
- **Special Events**: 70%

**Total Revenue**: $63,971

## Expenses

- **Fundraising**: 24%
- **Management & General**: 6%
- **Program Services**: 70%

**How MDA Spends $1**

**Note**: In 2023, $0.70 of every dollar MDA spends goes directly to our mission programs.
Join the Community

Instagram: @mdaorg  
Facebook: MDAorg  
X: @MDAorg  
LinkedIn: Muscular Dystrophy Association  
YouTube: YouTube.com/MDA

Advocacy X: @MDA_Advocacy  
TikTok: @mdaorg  
Twitch: MDA_LetsPlay  
Discord: MDA Let's Play